CUE Cue Biopharma Inc
Price (delayed)
$0.7901
Market cap
$48.84M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.72
Enterprise value
$35.11M
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the
Highlights
CUE's debt is down by 40% year-on-year and by 7% since the previous quarter
The EPS is up by 35% YoY and by 21% QoQ
CUE's revenue has surged by 69% year-on-year but it is down by 2.6% since the previous quarter
The gross profit has soared by 69% year-on-year but it is down by 2.6% since the previous quarter
The company's equity has shrunk by 53% YoY and by 31% QoQ
Cue Biopharma's quick ratio has decreased by 42% YoY and by 25% QoQ
Key stats
What are the main financial stats of CUE
Market
Valuations
Earnings
Shares outstanding
61.82M
Market cap
$48.84M
Enterprise value
$35.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.86
Price to sales (P/S)
4.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.78
Revenue
$9.29M
Gross profit
$9.29M
Operating income
-$41.5M
Net income
-$40.67M
EBIT
-$39.88M
EBITDA
-$37.53M
Free cash flow
-$36.3M
Per share
Balance sheet
Liquidity
EPS
-$0.72
EPS diluted
-$0.72
Free cash flow per share
-$0.64
Book value per share
$0.28
Revenue per share
$0.16
TBVPS
$0.57
Total assets
$32.19M
Total liabilities
$14.69M
Debt
$8.88M
Equity
$17.5M
Working capital
$11.45M
Debt to equity
0.51
Current ratio
1.84
Quick ratio
1.72
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
-404.1%
Gross margin
100%
Net margin
-438%
Operating margin
-446.9%
Return on assets
-93.9%
Return on equity
-172.1%
Return on invested capital
-979.4%
Return on capital employed
-215.5%
Return on sales
-429.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CUE stock price
How has the Cue Biopharma stock price performed over time
Intraday
5.35%
1 week
-20.55%
1 month
-35.76%
1 year
-56.59%
YTD
-27.51%
QTD
-13.27%
Financial performance
How have Cue Biopharma's revenue and profit performed over time
Revenue
$9.29M
Gross profit
$9.29M
Operating income
-$41.5M
Net income
-$40.67M
Gross margin
100%
Net margin
-438%
CUE's revenue has surged by 69% year-on-year but it is down by 2.6% since the previous quarter
The gross profit has soared by 69% year-on-year but it is down by 2.6% since the previous quarter
CUE's net margin has surged by 53% year-on-year and by 6% since the previous quarter
Cue Biopharma's operating margin has soared by 53% YoY and by 7% from the previous quarter
Growth
What is Cue Biopharma's growth rate over time
Valuation
What is Cue Biopharma stock price valuation
P/E
N/A
P/B
2.86
P/S
4.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.78
The EPS is up by 35% YoY and by 21% QoQ
The company's equity has shrunk by 53% YoY and by 31% QoQ
The P/B is 28% below the 5-year quarterly average of 3.8 and 2.9% below the last 4 quarters average of 2.8
The price to sales (P/S) is 93% lower than the 5-year quarterly average of 68.8 and 42% lower than the last 4 quarters average of 7.9
CUE's revenue has surged by 69% year-on-year but it is down by 2.6% since the previous quarter
Efficiency
How efficient is Cue Biopharma business performance
Cue Biopharma's return on equity has shrunk by 53% YoY and by 10% QoQ
The ROS has soared by 52% YoY and by 6% QoQ
The ROA has contracted by 32% YoY and by 7% from the previous quarter
The ROIC has decreased by 24% QoQ
Dividends
What is CUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CUE.
Financial health
How did Cue Biopharma financials performed over time
The total assets is 119% greater than the total liabilities
The total assets has declined by 48% year-on-year and by 28% since the previous quarter
Cue Biopharma's quick ratio has decreased by 42% YoY and by 25% QoQ
CUE's debt is 49% smaller than its equity
The company's equity has shrunk by 53% YoY and by 31% QoQ
CUE's debt is down by 40% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.